The announcement of topline data from a pivotal Phase 3 trial is a significant event for any biopharmaceutical company. Positive results could lead to regulatory approval and commercialization, boosting the stock price. Conversely, negative results could have the opposite effect. Given the importance of this data for NewAmsterdam Pharma's future, the short-term impact on the stock price is likely to be significant.